PI
Overview This project supports next generation sequencing (NGS) of samples from infants enrolled in the COG trial, AALL15P1. The aims are to 1) determine the rate of dominant clone detection by NGS at diagnosis of infant ALL and 2) correlate sequencing-based minimal residual disease with flow cytometry results and event-free survival for infants treated on AALL15P1. The results of this project will impact the design of future trials for infants with ALL.
|